{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T21:33:48Z","timestamp":1649194428781},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ci\u00eanc. sa\u00fade coletiva"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Abstract Since the enforcement of Generics Act (1999), three types of pharmaceutically equivalent products are marketed in Brazil: innovative reference (REF), \u201csimilar\u201d (S) and generic (G) drugs. The S (brand name) and G (generic name) borrow from REF (brand name) clinical data on safety and efficacy and dosage regimen. G (but not S) is bioequivalent to and interchangeable with REF. Starting in 2003, Brazilian Sanitary Surveillance Agency (Anvisa) has required data on relative bioavailability tests (with REF) to approve (or renew registration of) S drugs. In 2014, Anvisa extended interchangeability notion to similar drugs with a \u201ccomparable\u201d bioavailability, i.e., an \u201cequivalent\u201d similar drug (EQ). Drugs for chronic diseases and \u201ccritical dose medicines\u201d are listed among the EQ drugs approved. Interchangeability of nonbioequivalent medicines raises deep concerns regarding therapeutic failures and adverse events. Concerns are even more worrisome if patients switch from one drug to another during an ongoing treatment for illnesses such as epilepsy, congestive heart failure, hypertension, diabetes and\/or substitutable drugs have a narrow therapeutic index.<\/jats:p>","DOI":"10.1590\/1413-81232017228.04352017","type":"journal-article","created":{"date-parts":[[2017,8,8]],"date-time":"2017-08-08T18:28:41Z","timestamp":1502216921000},"page":"2549-2558","source":"Crossref","is-referenced-by-count":1,"title":["Nonbioequivalent prescription drug interchangeability, concerns on patient safety and drug market dynamics in Brazil"],"prefix":"10.1590","volume":"22","author":[{"given":"Francisco Jos\u00e9 Roma","family":"Paumgartten","sequence":"first","affiliation":[{"name":"Fiocruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Cecilia Amado Xavier de","family":"Oliveira","sequence":"additional","affiliation":[{"name":"Fiocruz,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Resolution RDC 58\/2014. Deals with agency\u2019s requirements for deciding that a similar drug is interchangeable with its reference medicine"},{"key":"ref2","series-title":"Estoque Regulat\u00f3rio da Anvisa"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1208\/s12248-009-9142-z","article-title":"Bioequivalence; Its History, Practice, and Future","volume":"11","author":"Midha KK","year":"2009","journal-title":"AAPS J"},{"key":"ref4","series-title":"Guidance for Industry. Statistical Approaches to Establishing Bioequivalence","year":"2001"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18773\/austprescr.2003.063","article-title":"Generics \u2013 equal or not?","volume":"26","author":"Birkett DJ","year":"2003","journal-title":"Aust Prescr"},{"key":"ref6","series-title":"Guideline on the investigation of bioequivalence","year":"2010"},{"key":"ref7","series-title":"Resolution RDC 133\/2003. Deals with agency\u2019s requirements for similar drug registration in Brazil"},{"key":"ref8","series-title":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - Anvisa. Resolution RDC 134\/2004. Deals with agency\u2019s requirements for introducing changes in the formulation and manufacturing process of registered medicines"},{"key":"ref9","series-title":"Federal Act 9787\/1999. Generics Act"},{"key":"ref10","series-title":"Resolution RE 1170\/2006. Guide for drug relative bioavailability\/bioequivalence tests"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1208\/s12248-013-9499-x","article-title":"International guidelines for bioequivalence of systemically available orally administered generic drug products: a survey of similarities and differences","volume":"15","author":"Davit B","year":"2013","journal-title":"AAPS J"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jsps.2013.05.001","article-title":"Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and Canada","volume":"22","author":"Galgatte UC","year":"2014","journal-title":"Saudi Pharm J"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1365-2125.2010.03872.x","article-title":"Generic substitution: a need for clarification","volume":"71","author":"Peterson GM","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.2010.03718.x","article-title":"Generic and therapeutic substitutions in the UK: are they a good thing?","volume":"70","author":"Duerden MG","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"ref15","doi-asserted-by":"crossref","DOI":"10.1001\/jama.282.21.1995-JFD90010-2-1","article-title":"From the Food and Drug Administration. Review of generic bioequivalence studies","volume":"282","author":"Henney JE","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures","volume":"71","author":"Berg MJ","year":"2008","journal-title":"Neurology"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1535-7511.2008.00261.x","article-title":"Generic antiepileptic drugs: current controversies and future directions","volume":"8","author":"Privitera MD","year":"2008","journal-title":"Epilepsy Curr"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1017\/S109285291200034X","article-title":"Generic substitution of antiepileptics: need for a balanced view","volume":"16","author":"Peterson GM","year":"2011","journal-title":"CNS Spectr"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","article-title":"The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs","volume":"25","author":"Borgherini G","year":"2003","journal-title":"Clinical Therapeutics"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1528-1167.2008.01927.x","article-title":"Debate: Substitution of generic drugs in epilepsy: is there cause for concern?","volume":"49","author":"Gidal BE","year":"2008","journal-title":"Epilepsia"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/j.1528-1167.2007.01272.x","article-title":"Generic products of antiepileptic drugs (AEDs): is it an issue?","volume":"48","author":"Bialer M","year":"2007","journal-title":"Epilepsia"},{"key":"ref22","series-title":"Reservation notes against generic substitution \u2013 solely medical considerations?","author":"Soinska-Schneider A","year":"2011"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1345\/aph.1Q349","article-title":"Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies","volume":"45","author":"Yamada M","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.ejim.2014.08.002","article-title":"Are generic and brand-name statins clinically equivalent? Evidence from a real data-base","volume":"25","author":"Corrao G","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"21","key":"ref25","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1001\/jama.2008.758","article-title":"Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis","volume":"300","author":"Kesselheim AS","year":"2008","journal-title":"JAMA"},{"issue":"Supl. 3","key":"ref26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.7175\/fe.v13i3S.312","article-title":"Essential to increase the use of generics in Europe to maintain comprehensive health care?","volume":"13","author":"Godman B","year":"2012","journal-title":"Farmacoeconomia.Health Economics and therapeutic pathways"},{"key":"ref27","series-title":"Federal Act 5772\/1971. Industrial Property Code"},{"key":"ref28","article-title":"Lei n\u00ba 6.360, de 23 de setembro de 1976. Disp\u00f5e sobre a Vigil\u00e2ncia Sanit\u00e1ria a que ficam sujeitos os Medicamentos, as Drogas, os Insumos Farmac\u00eauticos e Correlatos, Cosm\u00e9ticos, Saneantes e Outros Produtos, e d\u00e1 outras Provid\u00eancias. [Federal Act 6.360\/1976. Deals with sanitary surveillance of medicines, pharmaceutical ingredients, cosmetics, disinfectants and other products]","year":"1976","journal-title":"Di\u00e1rio Oficial da Uni\u00e3o"},{"key":"ref29","series-title":"Brasileiros ter\u00e3o mais op\u00e7\u00f5es na compra de medicamentos"},{"key":"ref30","series-title":"Bem Estar - Medicamento similar deve passar por testes de equival\u00eancia, prop\u00f5e Anvisa","author":"Mendes P"},{"key":"ref31","series-title":"Not\u00edcias. Aten\u00e7\u00e3o Farmac\u00eauticos. Publicada RDC que estabelece regras para intercambialidade de medicamentos similares com os de refer\u00eancia"},{"key":"ref32","article-title":"Anvisa muda regras para compra de medicamento similar","author":"Formenti L","journal-title":"Estad\u00e3o conte\u00fado. Estado de S\u00e3o Paulo"}],"container-title":["Ci\u00eancia &amp; Sa\u00fade Coletiva"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/csc\/v22n8\/1413-8123-csc-22-08-2549.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T18:46:50Z","timestamp":1504205210000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1413-81232017002802549&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1413-81232017002802549"],"URL":"https:\/\/doi.org\/10.1590\/1413-81232017228.04352017","relation":{},"ISSN":["1413-8123"],"issn-type":[{"value":"1413-8123","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}